Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 16Carcinoma, Non-Small-Cell Lung 14Ovarian Neoplasms 7Fallopian Tube Neoplasms 7Pancreatic Neoplasms 6Triple Negative Breast Neoplasms 5Lung Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Inflammatory Breast Neoplasms 3Adenocarcinoma of Lung 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Multiple Myeloma 2Melanoma 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms, Male 2Adenocarcinoma, Bronchiolo-Alveolar 2Adenocarcinoma Of Esophagus 2Adenocarcinoma 2Turcot syndrome 1Thrombocytosis 1Stages II-III Breast Cancer 1Stage IIIA Lung Non-Small Cell Cancer AJCC v7 1Stage IA Uterine Sarcoma 1Salivary Gland Neoplasms 1Recurrence 1Prostatic Neoplasms 1Primary Myelofibrosis 1

Interventions

Pemetrexed 3Carboplatin 3HM781-36B 2Gemcitabine 2pembrolizumab 1osimertinib 1aumolertinib 1aflutinib 1Taxes 1Paclitaxel 1Erlotinib Hydrochloride 1Clinical Trials, Phase I as Topic 1Cisplatin 1Bortezomib 1BID protein, human 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × NSCLC × Taxes × Clear all
NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

EQRx International, Inc.

Phase 3 Terminated
8 enrolled 7 charts
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡